5th HCV Therapy Advances_presentations

 Session 1: Current Treatment Options
 
Approved Regimens for Non Cirrhotic Patients
Dr. G. Foster, Queen Mary, University of London, UK
 
Approved Regimens for Cirrhotic Patients
Dr. M. Berenguer, La Fe University Hospital Valencia, Spain
 
Next Generation Regimens
Dr. J. Drenth, Radboud Universitair Medisch Centrum, the Netherlands
 Session 3: Treatment Challenges in Special Populations
 
Renal Failure
Dr. R. Esteban, Hospital Valle Hebron, Spain
 
Decompensated Cirrhosis
Dr. T. Berg, University Hospital Leipzig, Germany
 
Liver Cancer
Dr. M. Colombo, IRCCS Cà Granda Ospedale Maggiore Policlinico, Italy
 
Viral Co-Infection
Dr. M. Nelson, Chelsea and Westminster Hospital, UK
 Industry-Sponsored Session: DAA resistance from a clinical perspective
 
What every clinician should know about HCV resistance
Dr. C. Sarrazin, JW Goethe University Hospital, Germany
 
Clinical Case
Dr. Arends, University Medical Center Utrecht, The Netherlands
 
Clinical Case
Dr. C. Sarrazin, JW Goethe University Hospital, Germany
 
Clinical Case
Dr. S. Zeuzem, JW Goethe University Hospital, Germany
 Session 4: Treatment around the World (case based)
 
Patients in the US
Dr. F. Poordad, The Texas Liver Institute, USA
 
Patients in Germany
Dr. H. Wedemeyer, Medical School Hannover, Germany
 
Patients in Poland
Dr. R. Flisiak, Medical University of Bialystok, Poland
 
Patients in Holland
Dr. R. de Knegt, Erasmus Medical Center, the Netherlands
 
Patients in Spain
Dr. M. Buti, Hospital Valle Hebron, Spain
 Session 5: Resistance to DAAs
 
Resistance Case and Preventing Resistance
Dr. S. Chevaliez, Hôpital Henri Mondor, Université Paris XII, France
 
German Hepatitis C Resistance Registry
Dr. C. Sarrazin, J.W. Goethe University Hospital Frankfurt, Germany